Intra-subtype heterogeneity shapes treatment response in -rearranged ALL across all age groups
Zurich Open Repository and Archive (University of Zurich) · 01.02.2026
DOI: 10.5167/uzh-434595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zurich Open Repository and Archive (University of Zurich), erschienen am 01.02.2026. Verfasst von Alina Hartmann und 30 weiteren Autor:innen.
Abstract (Originalsprache)
KMT2A-rearranged B-cell acute lymphoblastic leukemia (r B-ALL) exhibits significant heterogeneity in age of onset, developmental origins, and clinical outcomes. The interplay of individual factors influencing early treatment response within this high-risk molecular subtype remains poorly elucidated. To identify determinants of early treatment response to induction chemotherapy, we analyzed 465 r B-ALL cases spanning a wide age range (1 month to 89 years) by integrating transcriptomic and genomic profiling with functional drug response and measurable residual disease (MRD) kinetics. We observed a strong inverse correlation between MRD clearance with advancing age (P = 2.1E-04), proximity to early B-cell-precursor developmental state (low maturity score, P = 1.3E-03), and as fusion partner (P = 7.0E-04). A multivariable analysis confirmed the strong impact of maturity (P = 0.02) and fusion partner (P = 0.03) on MRD clearance, supporting the concept that the cell's developmental state defines therapy response. Gene expression analysis identified cellular traits that relate to MRD clearance (e.g., chromatin organization, immune modulation, and proliferation). This gene expression classifier grouped cases not only by MRD clearance but also by ex vivo sensitivity to induction therapy drugs. Notably, good responders to ex vivo induction drugs were characterized by a higher maturity score (P = 1.8E-03), whereas for less mature r B-ALL cases, response profiles suggested higher Venetoclax sensitivity. Our study provides an integrative framework linking developmental phenotype, fusion partner, and MRD kinetics across the full age spectrum of r B-ALL. These insights may support future risk-adapted strategies and therapeutic targeting, particularly in immature r B-ALL.
Schlagwörter
Zitieren
APA
Hartmann, A., Bastian, L., Barz, M., Haas, J., Amelunxen, E., Ehm, P. A. H., Lenk, L., Kotrová, M., Beder, T., Steffen, F. D., Rauwolf, K. K., Wolgast, N., Bendig, S., Bozzetti, Cecilia, Alten, J., Mondal, M., Rademacher, A. V., Heymann, J., …, & Baldus, C. D. (2026). Intra-subtype heterogeneity shapes treatment response in -rearranged ALL across all age groups. Zurich Open Repository and Archive (University of Zurich). https://doi.org/10.5167/uzh-434595
Vancouver
Hartmann A, Bastian L, Barz M, Haas J, Amelunxen E, Ehm PAH, et al. Intra-subtype heterogeneity shapes treatment response in -rearranged ALL across all age groups. Zurich Open Repository and Archive (University of Zurich). 2026. doi:10.5167/uzh-434595
BibTeX
@article{Hartmann2026,
author = {Hartmann, Alina and Bastian, Lorenz and Barz, Malwine and Haas, Johannes and Amelunxen, Eric and Ehm, Patrick A. H. and Lenk, Lennart and Kotrová, Michaela and Beder, Thomas and Steffen, Fabio D. and Rauwolf, Kerstin Katharina and Wolgast, Nadine and Bendig, Sonja and Bozzetti and Cecilia and Alten, Julia and Mondal, Mayukh and Rademacher, Annika V. and Heymann, Julia and Walter, Wencke and Haferlach, Claudia and Ströh, Aeint-Steffen and Bergmann, Anke Katharina and Burmeister, Thomas and Gökbuget, Nicola and Bornhauser, Beat C. and Bourquin, Jean‐Pierre and Brüggemann, Monika and Schrappe, Martin and Cario, Gunnar and Baldus, Claudia Dorothea},
title = {Intra-subtype heterogeneity shapes treatment response in -rearranged ALL across all age groups},
journal = {Zurich Open Repository and Archive (University of Zurich)},
year = {2026},
doi = {10.5167/uzh-434595}
}
EUVIMED